Here we determined the impact of darolutamide, an AR antagonist with significant clinical efficacy in non-metastatic CRPC and metastatic hormone-sensitive prostate cancer [24,25] on the prostate cancer proteome. This evidence concerns the gene AR and prostate carcinoma.